Cardiovascular Complications of Respiratory Disorders

ERS has now resumed sales of printed books worldwide, with the exception of a small number of countries (https://www.ersbookshop.com/shipping-in-2020-4-w.asp). Electronic versions of many ERS books are available from our dedicated website at https://books.ersjournals.com/, or from Google Play Books, ebooks.com and the Amazon Kindle Store (in some territories), as well as from many library ebook vendors. For more information visit: https://books.ersjournals.com/ebooks-availability
 

Edited by Miguel Ángel Martínez-García, Jean-Louis Pépin and Mario Cazzola
This Monograph provides an update on cardiovascular disease complications and treatment implications for respiratory diseases, based on current scientific evidence and considered from an epidemiological, pathophysiological and clinical point of view. This book also discusses the true challenges when studying the complex relationship between these two groups of disorders.

This book contains a unique code that gives you free access to the eBook. If you would like to buy the eBook only and not receive a print copy, visit books.ersjournals.com

Contents list 
1. Epidemiological aspects of cardiovascular and respiratory diseases
2. Common pathophysiological pathways of the autonomic nervous system
3. Murine models of cardiovascular damage in lung diseases

Cardiovascular implications of specific respiratory disorders
4. Cardiovascular disease in COPD
5. Management of patients with asthma of COPD and cardiovascular disease: risks versus benefits
6. Chronic asthma and the risk of cardiovascular disease
7. Cardiovascular implications in bronchiectasis 
8. Cardiovascular complications of cystic fibrosis
9. Cardiovascular consequences of sleep disordered breathing: the role of CPAP treatment
10. The heart in obesity hypoventilation syndrome
11. Cardiovascular effects of innovative therapies in lung cancer
12. Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases
13. Cardiovascular mortality and morbidity in pulmonary embolism
14. The cardiovascular system in idiopathic pulmonary fibrosis
15. Cardiovascular consequences of community-acquired pneumonia and other pulmonary infections

Cardiovascular risk of pulmonary pharmacology
16. Beta2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities
17. Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists
18. Impact of inhaled corticosteroids in patients with cardiovascular disease
19. Cardiovascular side-effects of common antibiotics
20. The cardiovascular effects of xanthines and selective PDE inhibitors: a riskbenefit analysis

The Future
21. Future challenges

This book also includes clinical cases

ISBN 978-1-84984-118-4